Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lena E Friberg

Showing results (11-20 of 185) with videos related to

Pageof 19
Sort By:
Investigational New Drugs|August 28, 2009
Scaling the time-course of myelosuppression from rats to patients with a semi-physiological modelLena E Friberg, Marie Sandström, Mats O Karlsson
The Journal of Antimicrobial Chemotherapy|January 30, 2014
A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killingAmi F Mohamed, Otto Cars, Lena E Friberg
The Journal of Antimicrobial Chemotherapy|October 22, 2024
Therapeutic drug monitoring (TDM) of β-lactam/β-lactamase inhibitor (BL/BLI) drug combinations: insights from a pharmacometric simulation studyAmaury O'Jeanson, Elisabet I Nielsen, Lena E Friberg
Antimicrobial Agents and Chemotherapy|February 2, 2011
Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic modelElisabet I Nielsen, Otto Cars, Lena E Friberg
International Journal of Antimicrobial Agents|June 23, 2020
Pharmacodynamics of immune response biomarkers of interest for evaluation of treatment effects in bacterial infectionsAnders Thorsted, Elisabet I Nielsen, Lena E Friberg
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2020
Model-based Dose Individualization of Sunitinib in Gastrointestinal Stromal TumorsMaddalena Centanni, Sreenath M Krishnan, Lena E Friberg
Jac-Antimicrobial Resistance|March 12, 2025
A model-based evaluation of the pharmacokinetics-pharmacodynamics (PKPD) of avibactam in combination with ceftazidimeAmaury O'Jeanson, Elisabet I Nielsen, Lena E Friberg
Antimicrobial Agents and Chemotherapy|August 3, 2011
Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimizationElisabet I Nielsen, Otto Cars, Lena E Friberg
British Journal of Clinical Pharmacology|October 19, 2013
Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical responseBrendan C Bender, Emilie Schindler, Lena E Friberg
Investigational New Drugs|December 15, 2010
A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression modelAngelica Linnea Quartino, Lena E Friberg, Mats O Karlsson
Pageof 19

Showing results (11-20 of 185) with videos related to

Sort By:
Pageof 19
Investigational New Drugs|August 28, 2009
Scaling the time-course of myelosuppression from rats to patients with a semi-physiological modelLena E Friberg, Marie Sandström, Mats O Karlsson
The Journal of Antimicrobial Chemotherapy|January 30, 2014
A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killingAmi F Mohamed, Otto Cars, Lena E Friberg
The Journal of Antimicrobial Chemotherapy|October 22, 2024
Therapeutic drug monitoring (TDM) of β-lactam/β-lactamase inhibitor (BL/BLI) drug combinations: insights from a pharmacometric simulation studyAmaury O'Jeanson, Elisabet I Nielsen, Lena E Friberg
Antimicrobial Agents and Chemotherapy|February 2, 2011
Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic modelElisabet I Nielsen, Otto Cars, Lena E Friberg
International Journal of Antimicrobial Agents|June 23, 2020
Pharmacodynamics of immune response biomarkers of interest for evaluation of treatment effects in bacterial infectionsAnders Thorsted, Elisabet I Nielsen, Lena E Friberg
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2020
Model-based Dose Individualization of Sunitinib in Gastrointestinal Stromal TumorsMaddalena Centanni, Sreenath M Krishnan, Lena E Friberg
Jac-Antimicrobial Resistance|March 12, 2025
A model-based evaluation of the pharmacokinetics-pharmacodynamics (PKPD) of avibactam in combination with ceftazidimeAmaury O'Jeanson, Elisabet I Nielsen, Lena E Friberg
Antimicrobial Agents and Chemotherapy|August 3, 2011
Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimizationElisabet I Nielsen, Otto Cars, Lena E Friberg
British Journal of Clinical Pharmacology|October 19, 2013
Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical responseBrendan C Bender, Emilie Schindler, Lena E Friberg
Investigational New Drugs|December 15, 2010
A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression modelAngelica Linnea Quartino, Lena E Friberg, Mats O Karlsson
Pageof 19